CURRICULUM VITAE

Vivian Andrew Fonseca, M.D., FRCP
Professor of Medicine and Pharmacology
Tullis–Tulane Chair in Diabetes
Chief, Section of Endocrinology and Metabolism
Tulane University School of Medicine
Address: 1430 Tulane Avenue #8553, New Orleans, LA 70112
Office: (504) 988-4026; fax: (504) 988-6271
e-mail: vfonseca@tulane.edu

Academic Qualifications:

1. **M.B.B.S.** - 1974, Armed Forces Medical College, Poona, India.

2. **M.D.** - 1978, Bombay University.

3. **M.R.C.P. (U.K.)** Royal College of Physicians, London, 1980. **F.R.C.P.** - 2004

4. **SPECIALIST ACCREDITATION:** Completed Higher Specialist Training, accredited by the Royal College of Physicians (UK) in Internal Medicine, Diabetes and Endocrinology; 1987.

5. **DIPLOMATE:** American Board of Internal Medicine; 1993.

6. **DIPLOMATE:** American Board of Internal Medicine; Endocrinology, Metabolism and Diabetes; 1995

MEDICAL LICENSURE: New York (194117-1); Louisiana (12686 R)

AWARDS
American Diabetes Association, Banting Award for Leadership and Service, 2012
Southern Medical Association, Seale Harris Award for Clinical Research, 2012.
Best Doctors in the USA, 2012
Best Doctors in New Orleans, New Orleans Magazine, 2003, 2012
Alpha Omega Alpha Society, 2010
University of Arkansas for Medical Science, 1995 students award for Medical Education.
Best Doctors in Arkansas – 1996 - 1998, Arkansas Democrat Gazette

POSITIONS HELD:
1975 – 1976 Internship, King Edward Memorial Hospital, Bombay.

1976 - 1977	Senior House Officer - Internal Medicine, Bombay Hospital, St. George's Hospital, and J.J. Hospital, Grant Medical College, Bombay.
1977 - 1979	Registrar Internal Medicine, and Research Fellow K E. M. Hospital Bombay.
1979 - 1980	Senior House Officer Rotation, Internal Medicine; Oldchurch Hospital, Romford, Essex, U.K.
1981 - 1982	Registrar in Medicine and Diabetes, Queen Elizabeth Hospital, Welwyn Garden City, Herts, U.K.
1982 - 1983	Assistant Professor of Medicine and Endocrinology, Riyadh University, Saudi Arabia.
1983 - 1985	Research Fellow, Metabolic Unit, Royal Free Hospital, London.
1985 - 1992	Senior Registrar in Medicine, Diabetes and Endocrinology. (including one year in Nephrology and Transplantation: 1988). Royal Free Hospital, London. Appointed NHS Consultant Dec 1991.
1992 - 1996	Associate Professor of Medicine, Division of Endocrinology, University of Arkansas for Medical Sciences, Little Rock, and Staff Physician, Medicine/ Endocrinology, John L. McClellan Memorial Veterans' Hospital, Little Rock, Arkansas.
1996 – 1998	Professor of Medicine, Division of Endocrinology, University of Arkansas for Medical Sciences, Little Rock, and Staff Physician, Medicine/ Endocrinology, John L. McClellan Memorial Veterans' Hospital, Little Rock, Arkansas.
2009 - 2010	Chief, Division of Endocrinology, Texas A & M College of Medicine, Scott and White Clinic (part-time).
August, 1998	Professor of Medicine, Tullis –Tulane Alumni Chair in Diabetes, Section of Endocrinology, Adjunct Professor of Pharmacology, Tulane University Health Sciences Center, New Orleans. Chief, Section of Endocrinology (2003- present).

CURRENT RESPONSIBILITIES

1. Medical Director, Tulane Hospital Diabetes Education Program (ADA Recognised)
2. Staff Physician, New Orleans VA Hospital High Risk Diabetes Clinic.
3. Staff Physician, University Medical Center of Louisiana, New Orleans

4. Member, Advisory Committee, Clinical Trials Unit – Funded by NIH and Tulane (previously Associate Director of the GCRC)
5. Tulane Center for Aging and Regenerative Medicine (COBRE) – Associate Director
6. Faculty of Tulane Xavier National Center of Excellence in Women's Health.
7. Tulane University Health Sciences Center, Graduate Medical Education Committee.
8. Tulane University Health Sciences Center. Research Advisory Committee; Promotion and Honors Committee. Previous Service: University Senate; Grievance Committee; Hospital Bylaws Committee

NATIONAL PROFESSIONAL ACTIVITIES

American Diabetes Association:
President, Science and Medicine – 2012
Member, National Board of Directors, 2005-2008 and 2010- 2013
National Leadership Council and Executive Committee
Significant role in development of current Strategic Plan and new research initiative – "Pathway to a Cure"
Professional Practice committee (Chairman 2004 - 2006)
Diabetes Care – Editor in Chief – 2006 - 2011
Disaster Preparedness Task Force – 2006 Chair
Research Policy Committee – 2007-2009
In –Patient Diabetes Management Conference -2006, Co –Chair;
Cardiovascular 'Make the Link' Committees Co –Chair –jointly with ACC and AHA Editorial and review activities listed below
Annual Post-Graduate Course – Organizing committee and Session Chair

American College of Endocrinology:
Board of Trustees

American Association of Clinical Endocrinologists:
Member Board of Directors - 2016:
ACE/ACE Patient Education and Awareness Committee
AACE Education Services (AES) Oversight Group
Annual Meeting Oversight Committee
Fellows-in-Training Committee
AACE/ACE Task Force to Update the Comprehensive Diabetes Management Algorithm
Legislative and Regulatory Committee
Food and Drug Administration
Diabetes Scientific Committee
Lipids Scientific Committee
Previous Service: Clinical Research Committee, Publications Committee, Academic Affairs Committee

American Heart Association:
Council on Nutrition, Physical Activity and Metabolism

Journal of Diabetes and its Complications:
Editor in Chief, 2012 - present

National Institutes of Health:
1. ACCORD trial, Glycemia Working group, Ancillary Studies Committee
2. CRIC study: Ancillary Studies Committee
3. TINSAL 2D – Co-PI and Steering Committee
4. GRADE Trial – Protocol implementation committee
5. D2D Trial – Recruitment and Retention committee
6. Several Study Sections and Review Panels

PROFESSIONAL AFFILIATIONS
The Endocrine Society
American Diabetes Association (see above for role)
American Heart Association
International Diabetes Federation.
American Association of Clinical Endocrinologists (Fellow)
American College of Physicians (Fellow)
Royal College of Physicians, London (Fellow)
National Diabetes Education Initiative (Executive Committee)
Council for the Advancement of Diabetes Research and Education
Southern Society for Clinical Investigation
Ethic Ad Council (National Advisory Board, 1999 -2002)
Louisiana Health Care Review (Member, Advisory Board, 2001 -2005)
New Orleans Academy of Internal Medicine (Advisory Board, President 2002-2003)

Editorial/Ad hoc reviewer:
Diabetes Care: Editor in Chief 2007- , Associate Editor 2002- 2006, Global Literature Editor 2000 - 2006
Journal of Diabetes and its Complications, Editor in Chief, 2012 - present
Metabolic Syndrome and Related Disorders: Editor in Chief; 2004 - 2006, Associate Editor 2002 - 2004
Editorial Board: Journal of Clinical Endocrinology and Metabolism (2003-2006), Journal of Applied Research, Int Journal of Impotence Research and Sexual Medicine (Nature Pub Group), Current Diabetes Reports: Literature Alert Editor 2001-2004
Reviewer for Journals: New England Journal of Medicine, The Lancet, JAMA, Diabetes Care, Kidney International, Metabolism, Diabetic Medicine, British Medical Journal, Clinical Endocrinology, Peptides, Am J of Physiology, Am J Med Science. Am J Clin Nutrition, Endocrine Practice.
Scientific Reviewer: NIH – DRTC Program, Special Review panel – "Bench to bedside research in diabetes", Program Project grants in Diabetes, Several Special Emphasis Panels
NCCAM Mechanistic grants in Diabetes program
VA Co-operative Studies Program, VA – JDF program projects.

American Diabetes Association, National Meeting Abstract reviewer

RESEARCH INTERESTS AND FUNDING

ACTIVE

Ongoing Research Support

1P20GM109036-01A1 (He) 03/10/2016 - 02/28/2021 0.60 calendar
NIH
Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases
The objective of this COBRE is to develop the careers of promising junior investigators in cardiometabolic disease research and to build programmatic strength in this area. Career development will utilize a strong core of research mentors who will provide career development advice as well as sound practical advice on scientific development and laboratory management.
Role: Co-PI

1P20GM103629 (Jazwinski) 08/1/2012 - 12/31/2017 0.60 calendar
NIH
Mentoring Research Excellence in Aging and Regenerative Medicine
The objective of this COBRE is to develop the careers of promising junior investigators in biomedical aging research and to build programmatic strength in this area. Career development will utilize a strong core of research mentors who will provide career development advice as well as sound practical advice on scientific development and laboratory management.
Role: Co-PI

1RO1DK096549-01A1 (Coca) 07/01/2012 – 06/30/2017 0.60 calendar
NIH/NHBLI
Novel Serum and Urinary Biomarkers of Diabetic Kidney Disease
The two major goals of this study are to 1) identify biomarkers for primary prevention of incident diabetic kidney disease and for secondary prevention of progressive kidney disease; and 2) to better understand the renal outcomes of ACCORD in relation to the applied interventions. The ultimate goal is to identify better surrogates or therapeutic targets for kidney disease in diabetics.
Role: Co-PI

CDRN-1306-04864 03/15/2014 - 09/14/2018 2.40 calendar
PCORI/LPHI
Louisiana Clinical Research Data Network
The LACDRN will increase the capacity to conduct robust comparative effectiveness research by building a health information technology infrastructure that provides access to comprehensive clinical data for more than one million patients statewide.

U54GM104940-01 08/12/2012 - 06/30/2017 1.20 calendar
NIH/Pennington

Louisiana Clinical & Translational Science Center
The LA CaTS Center represents a unified, comprehensive approach targeting the theme of "prevention, care and research of chronic diseases in the underserved population".

1U54GM04940 Norton (PI) 07/01/2015 - 06/30/2016 0.60 calendar
LA/CaTS
Vaccine Efficacy in Diabetic and Elderly Patients
The purpose of this study is to determine if an individual's level of inflammation determines their response to vaccination
Role: Co-PI

OB-1402-10977 (Katzmarzyk) 01/01/2016 - 12/31/2016 0.60 calendar
PCORI/Pennington
The PROPEL Study
The primary aim of this study is to develop and test the effectiveness of a 24 month, patient-centered, pragmatic and scalable obesity treatment program delivered with primary care, inclusive of an underserved population.
Role; Co-Investigator

Navar (PI) Jansenn
Effect of Canagliflozin on intra-renal angiotensinogen

Completed Research Support
HHSN268201100027C (Fonseca) 06/01/2011 – 12/31/2014 1.20 calendar
NIH/NHBLI
ACCORDION: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study
The ACCORD study was designed to see if medical treatments could reduce the heart attack and stroke rate in people with diabetes. ACCORDION is an observational follow up study that will be done over the next 3½ years to see if the effects of the ACCORD treatments change over time.
Role: PI

1-U01-DK098246-01(Nathan) 12/01/2012 – 09/30/2014 2.40 calendar
NIH/NIDDK $3,672,726
The Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (The GRADE Study)
The primary aim of the GRADE Study is to examine five different medications that are commonly used to treat type 2 diabetes and compare their effectiveness in lowering and maintaining HbA1c levels over time in recent-onset type 2 diabetes when used in combination with metformin. In addition, other attributes of the medication combinations, including adverse events, acceptability, and effects on cardiovascular risk factors, quality-of-life, and other outcomes, will be compared. Finally, in a subset of the study cohort, the relative effects of early combination therapy will be compared with the traditional sequential approach.

U01 DK098245-01 (Pittas) 10/01/2012 - 06/30/2014 2.40 calendar
NIH/NIDDK
Vitamin D to Prevent Type 2 Diabetes (The D2d Study)
The primary aim of the D2d study is to determine the effectiveness of Vitamin D is preventing Type 2 diabetes mellitus.

1R21DK094006-01(Fonseca; Navar) 08/15/2012 - 07/31/2014 1.20 calendar
NIH
Potential of Urinary AGT as a Novel Biomarker for Intrarenal RAS Activity in Type 1 Diabetes Mellitus
The purpose of this research study is to investigate a more sensitive and specific test for determining the early presence of diabetes nephropathy, a disease of the kidneys.
Role: Co-PI

IIR-09-358-2 (Miller) 11/01/2010 – 10/31/2013 0.24 calendar
VA/HSR&D
Safety and Effectiveness Evaluations for Diabetes
Using up to 15 years of linked longitudinal national data, we will apply previously developed methodologies to compare medications for diabetes patients in terms of their safety and effectiveness**.** Drug-to-drug comparisons will be made among medications initially prescribed at different points in the course of diabetes treatment.
Role: Co-PI

1R01HL110395-01 (Fonseca; Hempe) 09/21/2011 - 07/31/2013 1.20 calendar
NIH/NHLBI
Impact of Biological Variation in A1c on Mortality, Cardiovascular Events, and Hypertension
The purpose of this study was to test the association between high HGI and total mortality and hypoglycemia and the ACCORD glycemia intervention trial.

1 R01 HL104071-01 (Shah) 08/15/2010 - 06/30/2012 0.60 calendar
NIH/NHLBI
Carbamylated Low-Density Lipoprotein and Cardiovascular Events
The overall goal of this proposal is to utilize the wealth of information that will be gathered as a part of the CRIC study sponsored by NIDDK to analyze the relevance of nontraditional risk factors for cardiovascular disease that are fairly specific for patients with renal insufficiency.
Role: PI

N01 HC 95182 (Fonseca) 01/01/2003 - 12/31/2011 2.40 calendar
NIH/NHBLI
Action to Control Cardiovascular Risk in Diabetes (ACCORD Trial)

The overall goal of this trial is to test three complementary medical treatment strategies for type 2 diabetes to enhance the options for reducing the still very high rate of major CVD morbidity and mortality in this disease.

U01 DK074556-02 (Goldfine) 01/01/2006 – 12/31/2011 1.80 calendar
NIH
Targeting Inflammation Using Salsalate for Type 2 Diabetes
The primary objective of the study is to determine whether salicylates represent a new Pharmacological option for diabetes management.
Role: PI

1 R01 DK081373-01A2 (Barzilay) 09/01/2010 – 03/31/2011 0.60 calendar
NIH/NIDDK
Salsalate: A Diabetes Treatment for Carbonyl, Oxidative & Nitrosative Stress
This is an ancillary study to the TINSAL T2D trial attempting to study whether salsalate favorably affects oxidative stress independent of glycemic changes.
Role: PI

72-06-CR-58 (Fonseca) 07/01/2006 -12/31/2009 2.40 calendar
American Diabetes Association
Impact of Hurricane Katrina on Diabetes and Co-Morbidities
Hurricane Katrina has had a significant impact on the health of people with diabetes, and that this impact may have long-lasting health and economic implications.

DK 58499 (Agrawal) 07/01/2001 - 06/30/2005 0.60 calendar
NIH
Protease Inhibitor Related Adipogenesis in HIV Infections
The major goal of this project is to examine the effects of protease inhibitors and HIV proteins in adipocytes differentiation.

Previous investigator initiated funding (selected)
Arkansas State Diabetes Control Program 1995 –1998 – CDC (Co PI 15% effort)

Treatment of Hyperhomocysteinemia – American Heart Association 1996 – 1998. PI – 20% effort

American Heart Association - "Modulation of Homocysteine Metabolism by PPAR Agonists" 2001-2003. (PI -20% effort).

Detection and Treatment of Myocardial Ischemia in Asymptomatic Patients with Diabetes" - (The DIAD Study) PI – Yale University consortium 2000-2005

Protease Inhibitor Related Adipogenesis in HIV Infections. NIH #DK58499. 1999-2004 Co –PI. PI K Agrawal. 5% effort

Mechanisms of HAART-induced endothelial dysfunction NIH # 1RO1HL73691-01A1 PI. PI K Agrawal. 5% effort, 7/1/03-6/30/07

The Effect of Chronic Sildenafil Administration on Biochemical Markers of Endothelial Dysfunction" PI. Pfizer, Viagra competitive grants program 2003

"Effect of Pioglitazone (Actos) on Endothelial Function Inflammation and Plasma Homocysteine in Type 2 Diabetes" Takeda pharmaceuticals – investigator initiated grant

"A Comparison of Humalog Mix 75/25 with Humulin 70/30 in Insulin Requiring Diabetes" (Investigator Initiated) Funded by Eli-Lilly

"The Effect of Carvedilol and Metoprolol on Proteinuria and Endothelial Function in African-American Patients With Diabetes, Hypertension and Nephropathy"

Effect of Duration of Insulin Pump Tubing on Glycemic Control in Type 1 Diabetes. Novo Nordisk (Investigator Initiated)

Impact of Hurricane Katrina on Diabetes and Co-Morbidities. American Diabetes Association, Clinical Research Grant, 2006- 2009. PI – 20% effort.

Chronic Renal Insufficiency Cohort Study (CRIC) NIDDK, 2002 –2007 5% effort

Predicting Microalbuminuria in type 2 diabetes -(ACCORD ancillary study); NIH SBIR, co- PI, PI Patrick Walker, 10% effort

Effect of Insulin on Carotid Intimal Thickness in Zucker Fatty Rats (Sanofi Aventis, Investigator Initiated) 10%

Effect of Exentatide on Carotid Intimal Thickness in Zucker Fatty Rats (Lilly - Amylin, Investigator Initiated) 10%

Effect of Levemir Insulin on Carotid Intimal Thickness in Zucker Fatty Rats (Novo Nordisk, Investigator Initiated)

All to Target Trial-Lantus (Insulin Glargine) with Stepwise Addition of Apidra (Insulin Glulisine) or Lantus with One Injection of Apidra vs. a Twice-Daily Premixed Insulin Regimen (Novolog Mix 70/30)

Diabetes Remote Monitoring System (Eli Lilly, and Medadherence. Investigator Initiated) Fonseca (PI)

Forearm Endothelial Function in Non-Insulin Dependent Diabetic Patients with Nephropathy: Effect of Vitamin D Analog (Investigator Initiated) - Funded by Abbott and Scott and White Healthcare

Previous Clinical Trials (Selected from over 100 multi-center trials completed):

1. Troglitazone monotherapy and combination with insulin in NIDDM. (Parke-Davis and Sankyo)
2. Aminoguanidine in diabetic nephropathy. (Alteon)
3. HOE 901 Insulin (Glargine) in IDDM and NIDDM (Hoechst)
4. Domperidone in diabetic gastroparesis. (Janssen)
5. Erb:Yag lasers to obtain blood samples, without a needle. (Venisect Inc).
6. Gabapentin in Diabetic Neuropathy. (Parke -Davis)
7. Viagra in diabetic patients with erectile dysfunction (Pfizer)
8. GI252670 in Diabetes Mellitus (Glaxo Wellcome)
9. Triple Drug therapy for type 2 DM (Parke Davis, Smith Kline Beecham)
10. Slow release Metformin in Type 2 DM (Bristol Myers Squibb)
11. Zenerestat and Zoplorestat for Diabetic Neuropathy (Parke Davis and Pfizer)
12. Insulin Pumps in type 2 Diabetes (Minimed)
13. Low Dose Glucotrol XL in type 2 Diabetes (Pfizer).
14. Comparison of HMR 1964 insulin and Regular insulin type 2 diabetes (Aventis)
15. A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus (Gemini)
16. Lamotrigine in Diabetic Neuropathy
17. Vildagliptin in Type 2 Diabetes
18. Inhaled insulin in type 2 diabetes – several trials (Pfizer)
19. Biodel and Halozyme rapid acting insulins

TEACHING AND MENTORSHIP

Program Director – Tulane Endocrinology Fellowship Program
Several Fellows are in leading academic programs as faculty. Others are in prominent clinical practices, playing a significant leadership role in clinical programs and trials. A few are listed here with subsequent position:

Medha Munshi, MD	1993 - 1995	Associate Professor	Harvard University
Suresh Baliga, MD	1995 - 1998	Associate Professor	Mount Sinai Medical School
Akhil Parulkar, MD	1998 - 2000	Associate Professor, Medicine	Tulane University School of Medicine
Cyrus DeSouza, MD	1999 - 2001	Professor of Medicine, Chief of Endocrinology	University of Nebraska

Sunil Asnani, MD	2002 - 2004	Associate Professor, Medicine	Rutgers New Jersey Medical School
Tina Thethi, MD	2004 – 2006	Associate Professor, Medicine	Tulane University School of Medicine
Brandi Pannunti, MD	2004 – 2006	Chief of Endocrinology	Ochsner Medical Center
Andrea Zombok, PhD		Associate Professor, Pharmacology	Tulane University School of Medicine, Tulane Center for Hypertension – COBRE
Shengxu Li, PhD		Associate Professor, Epidemiology	Tulane University School of Public Health and Tropical Sciences, Tulane BIRCWH Program

INVITED LECTURES (not listed)

I have been invited to speak and chair at several national and international conferences such as EASD (annually for the last 10-12 years), EASD, IDF, AHA, ACC, etc.

PUBLICATIONS

BOOKS AND BOOK CHAPTERS

1. *Clinical Diabetes: Translating Research into Practice*. Fonseca V Editor, El Sevier, 2006
2. *Cardiovascular Endocrinology*. Editor, Humana Press; 2008
3. *Therapeutic Strategies for the Metabolic Syndrome*, Editor, Clinical Publishing, Oxford 2008
4. *Handbook of Diabetes*, Editor, Current Medical Group 2008
5. De'Souza C, Pendergrass M, Fonseca V. *The Insulin Resistance Syndrome and its Vascular Complications*. Goldstein BJ, Muller – Wieland D. Martin Dunitz, 2003
6. Theuma P and Fonseca VA. *Is Diabetic Erectile Dysfunction more difficult to treat?* In Oral Pharmacotherapy for Male Sexual Dysfunction. Broderick GA. Humana Press. 2005
7. Oxford American University Press –*Treating Diabetes to Goal* 2010

PEER REVIEWED PAPERS AND REVIEWS

1. **Fonseca V,** Deb J, Bhandarkar SD. Chlorpropamide induced syndrome of inappropriate anti-diuretic hormone secretion. J Postgrad Med 1980;26:127-30

2. **Fonseca V,** Phear D. Hyperosmolar non-ketotic diabetic syndrome precipitated by diuretic therapy. Br Med J 1982;284:36-37

3. Dandona P, **Fonseca V,** Mier A, Beckett AG. Diarrhoea and Metformin in a diabetic clinic. Diabetes Care 1983; 6:72-74

4. Dandona P, **Fonseca V,** Mier A, Beckett AG. Diabetes and bowel habits. N Engl J Med 1983; 308:1227-8.

5. **Fonseca V,** Ramage P, Mikhailidis DP, Dandona P. Ketanserin in intermittent claudication. Lancet 1984; ii:1212-3.

6. Dandona P, Bolger J, Boag F, **Fonseca V,** Abrams JD. Proliferative retinopathy and diabetes mellitus. Lancet 1984; i:1294.

7. **Fonseca V,** Mikhailidis DP, Dandona P. Association of hyperglycaemia with hyponatraemia. Br Med J 1984; i:1834-5.

8. **Fonseca V,** Mohiuddin J, Weerakoon J, Boss M, Mikhailidis D, Dandona P. Plasma creatinine and creatinine clearance in nutritional osteomalacia. Lancet 1984; i:1093-5.

9. **Fonseca V,** Tongia R, Abu-Aisha H. Sunlight exposure and vitamin D deficiency in Saudi Arabian women. Postgrad Med J 1984; 60:589-91.

10. Dandona P, Mohiuddin J, Weerakoon J, Freedman D, **Fonseca V,** Healey T. Persistence of parathyroid hypersecretion following vitamin D treatment in Asian vegetarians. J Clin Endo Metab 1984; 59:535-9.

11. **Fonseca V,** Khoker A, Dandona P. Insulin receptor antibodies causing steroid responsive diabetes. Br Med J 1984;288:1578

12. Dandona P, Bolger J, Boag F, **Fonseca V,** Abrams JD. Rapid development and progression of retinopathy following strict diabetic control. Br Med J 1985; 290:895-6

13. **Fonseca V,** Mikhailidis DP, Boag F, Jeremy JY, Barradas M, Gracey L, Dandona P. Thrombocytopenia, lupus-like anticoagulant and peripheral vascular disease : response to prostacyclin infusions. Angiology 1985; 36:258-63.

14. **Fonseca V,** Havard CWH. Electrolyte abnormalities and cardiac failure associated with hypomagnesaemia and anorexia nervosa. Br Med J 1985; 291:1680-82.

15. **Fonseca V,** Houlder S, Thomas M, Kirk RM, Dandona P. Vitamin D deficiency following vagotomy. Br Med J 1985; 290:1946.

16. Dandona P, Junglee D, Katrak A, **Fonseca V,** Havard CWH. Increased serum pancreatic enzymes after treatment with methylprednisolone: possible evidence of subclinical pancreatitis. Br Med J 1985; 291:24.

17. Dandona P, **Fonseca V,** Baron DN. Hypoalbuminaemic hyponatraemia - a new syndrome. Br Med J 1985; 391:1253-5.

18. **Fonseca V,** Tongia R, Laajam M. Non-ketotic diabetes in young non-obese Saudi Arabians. E Afr Med J 1985; 62:27-31.

19. **Fonseca V,** Berger L, Beckett AG, Dandona P. Pancreatic size in diabetes mellitus: a study based on ultrasound. Br Med J 1985; 291:1240-41.

20. Dandona P, **Fonseca V,** Thomas PK, Llewellyn G, Bolger J. Painful diabetic neuropathy. Lancet 1985; i: 697.

21. **Fonseca V,** Agnew J, Dandona P. Secondary hyperparathyroidism and bone density. Br Med J 1985; 290:555-6.

22. **Fonseca V,** D'Souza V, Houlder S, Thomas M, Wakeling A, Dandona P. Osteopenia in women with anorexia nervosa. N Engl J Med 1985; 313:326.

23. Dandona P, **Fonseca V,** Baron DN. Hyponatraemia and hypovolaemia. N Engl J Med 1985; 313:387-8.

24. Mikhailidis DP, **Fonseca V,** Dandona P. Pituitary apoplexy. Br Med J 1985; 291:488-9.

25. **Fonseca V,** Berger L, Beckett AG, Dandona P. Pancreas in non- insulin dependent diabetes. Lancet 1985; ii:667.

26. **Fonseca V,** Epstein O, Katrak A, Junglee D, Mikhailidis D, McIntyre N, Dandona P. Serum immunoreactive trypsin and pancreatic lipase in primary biliary cirrhosis. J Clin Pathol 1986;39:638-40.

27. Llewellyn JG, Thomas PK, **Fonseca V,** King RHM, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropath. 1986; 72: 157-63.

28. **Fonseca V,** Brown R, Hochauser D, Ginsburg J, Havard CWH. Acute adrenal crisis precipitated by thyroxine. Br Med J 1986; 2:1185-6.

29. Dandona P, Boag F, **Fonseca V,** Menon RK. Diabetes mellitus and pregnancy. N Engl J Med 1986; 315:58.

30. Dandona P, **Fonseca V,** Junglee D, Katrak A, Mikhailidis DP. Relationship between severity of diabetes and pancreatic exocrine dysfunction. Diab Res Clin Prac 1986; 1:303-4.

31. Dandona P, **Fonseca V,** Menon RK. Vitamin D deficiency and the endocrine pancreas. Diabetologia 1986; 29:468-9.

32. **Fonseca V,** D'Souza V, Agnew J, Mikhailidis D, Wakeling A, Dandona P. Biochemical abnormalities in anorexia nervosa and bulimia. Ann Clin Biochem 1987; 643-4.

33. Dandona P, **Fonseca V,** Beckett AG. Subcutaneous insulin resistance syndrome. N Engl J Med 1987; 316:50.

34. **Fonseca V,** Menon RK, O'Brien PMS, Dandona P. Successful pregnancy in a diabetic controlled with intraperitoneal insulin. Diabetes Care 1987; 10:541-2.

35. Khokher MA, Avasthy N, Taylor AM, **Fonseca V,** Dandona P. Insulin-receptor antibody and hypoglycaemia associated with Hodgkins disease. Lancet 1987; i:693-4.

36. Dandona P, **Fonseca V,** Mikhailidis DP, Menon RK. Insulinoma presenting as alcoholic stupor. Postgrad Med J 1987; 63:39-40.

37. **Fonseca V,** Bloom R, Dick R, Dandona P. Tetany despite normocalcaemia and normomagnesaemia following parathyroidectomy. Postgrad Med J 1987;63:885-6.

38. **Fonseca V,** Menon RK, O'Brien PMS, Fernando O, Stephen R, Dandona P. Diabetic pregnancy managed with intraperitoneal insulin. Diab Med 1987;4:74-76.

39. **Fonseca V,** Dandona P, Havard CWH. Diabetes mellitus following hypophysectomy for acromegaly. Br Med J 1987; 294:413-14.

40. Dandona P, **Fonseca V,** Fernando O, Menon RK, Weerakoon J, Kurtz A, Stephen R. Control of diabetes through a subcutaneous peritoneal access device (SPAD) in patients with resistance to subcutaneously injected insulin. Diab Res 1987; 5:47-50.

41. Barradas M, Mikhailidis DP, Epemolu O, Jeremy JY, **Fonseca V,** Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987; 67:451-7.

42. Mikhailidis DP, **Fonseca V,** Barradas M, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (ORG 10172). Br J Clin Pharm 1987; 24:415-24.

43. **Fonseca V,** Epstein O, Gill DS, Menon RK, McIntyre N, Dandona P. Hyperparathyroidism and low serum osteocalcin despite Vitamin D replacement in primary biliary cirrhosis. J Clin Endo Metab 1987; 64:873-7.

44. **Fonseca V,** D'Souza V, Houlder S, Thomas M, Wakeling A, Dandona P. Vitamin D deficiency and low osteocalcin concentrations in anorexia nervosa. J Clin Path 1988; 41:195-7.

45. **Fonseca V,** Agnew J, Nag D, Dandona P. Bone density and cortical thickness in nutritional osteomalacia: effect of secondary hyperparathyroidism. Ann Clin Biochem 1988; 25:271-4.

46. Mikhailidis DP, **Fonseca V,** Barradas M, Hutton R, Jeremy J, Epstein O, McIntyre N, Dandona P. Platelet aggregation and thromboxane A2 release in primary biliary cirrhosis: effect of d-penicillamine therapy. Prostagland Leukotr Med 1988; 31:131-8.

47. Gill DS, Barradas M, **Fonseca V,** Gracey L, Dandona P. Increased histamine content in leucocytes and platelets of patients with peripheral vascular disease. Am J Clin Pathol 1988; 41:195-7.

48. **Fonseca V,** Mikhailidis DP, Barradas M, Jeremy JY, Gracey L, Dandona P. Double blind placebo controlled trial of Buflomedil in intermittent claudication. Int.J.Clin Pharm Res; 1988; 8:377-81.

49. Ejim O, **Fonseca V,** Coumar A, Mathur S, Bell J, Dandona P. Plasma fibronectin concentrations in peripheral vascular disease. Clin Chem 1988; 34:2426-29.

50. Gaylarde PM, **Fonseca V,** Llewellyn G, Sarkany I, Thomas PK, Dandona P. Transcutaneous oxygen in the legs and feet of diabetics. Diabetes 1988; 37:714-16.

51. Barradas MA, Gill DS, **Fonseca V,** Mikhailidis DP, Dandona P.Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18:399-404.

52. **Fonseca V,** Havard CWH. Portal hypertension secondary to azathioprine in amyasthenia gravis. Postgrad Med J 1988; 64: 950- 952.

53. **Fonseca V,** Thomas M, Havard CWH. Hashitoxicosis with antibodies interfering with thyroid function tests. J Roy Soc Med 1988; 81:546-7.

54. Llewelyn JG, Thomas PK, **Fonseca V**, Dandona P. Acute painful diabetic neuropathy. Diabetes Care 1988, 11:748-9.

55. **Fonseca V,** Thomas M, Gill DS, Dandona P. Prolonged Vitamin D Deficiency and autonomous hyperparathyroidism. Br. Med. J. 1989, 299:626.

56. **Fonseca V,** Ames D, Ginsburg J. Insulinoma causing hypoglycaemia for 26 years. J Roy Soc Med 1989, 82:437-8.

57. Barradas MA, **Fonseca V**, Mikhailidis DP, Dandona P. The effect of Iloprost infusion on platelet function in patients with peripheral vascular disease. J. Drug. Dev. 1989, 2:147 -153.

58. Gill DS, Barradas M, **Fonseca V,** Dandona P. Plasma histamine concentrations are elevated in diabetes mellitus and peripheral vascular disease. Metabolism 1989; 38:243-47.

59. **Fonseca V,** Thomas M, Hamilton G, Dick R, Dandona P. Elevated gonadotrophins in men with peripheral vascular disease and impotence. Br Med J 1989; 298: 163-4.

60. **Fonseca V,** Bell J, Dandona P. A combination of Insulin and Glibenclamide in non-insulin-dependent diabetes with secondary drug failure. Practical Diabetes, 1990; 7:257-59.

61. **Fonseca V,** Havard CWH. Long-term treatment of myasthenia gravis with azathioprine. Postgrad Med J 1990; 66:102-5.

62. **Fonseca V**, Havard CWH. The natural course of myasthenia gravis. Br. Med. J. 1990; 300:1409-10. (Invited Editorial).

63. Havard CWH, **Fonseca V.** New approaches to the treatment of myasthenia gravis. Drugs 1990; 39:66-73.

64. **Fonseca V,** Boag F, Evans TR, Havard CWH. Hypopituitarism following coronary bypass surgery. Hosp.Update. 1990; 16:552-3.

65. **Fonseca V**., Wakeling A., Havard CWH. Hyperthyroidism and eating disorders. BMJ. 1990; 301:322-3.

66. **Fonseca V,** Baillod RA, Berger LA, Fernando ON, Moorhead JF. Splenic abscess in patients on haemodialysis. Am.J.Kid.Dis. 1990; 15:273-275.

67. **Fonseca V**, Ball S, Marks V, Havard CWH. Hypoglycaemia associated with anorexia nervosa. Postgrad Med J 1990, 66:102-5.

68. Gill D, **Fonseca V**, Barradas MA, Baillod R, Moorhead JF, Dandona P. Plasma histamine concentrations in chronic renal failure. J Clin Pathol 1991, 44:243-5.

69. **Fonseca V**. Medical complications of eating disorders. Hosp. Update. 1991

70. **Fonseca V**. Cigarette smoking and the thyroid. J Smoking. Rel. Dis. 1991; 2:101-4.

71. Barradas M, **Fonseca V**, Gill D, Jeremy JY, Varghese Z, Baillod R, Moorhead JF, Dandona P. Intraplatelet serotonin, beta - thromboglobulin, histamine and thromboxane synthesis in renal disease. Am J Clin Path. 1991, 96:504-11.

72. **Fonseca V,** Thomas M, Sweny P, Moorhead JF. Can urinary thyroid hormone loss cause hypothyroidism? Lancet 1991, 338:475-6.

73. **Fonseca V**, Thomas M, Dusheiko G. Thyrotrophin receptor antibodies following recombinant alpha interferon treatment for viral hepatitis. Acta Endocrinol, 1991; 125:491-3.

74. **Fonseca V.** Medical management of the diabetic foot. Treating Diabetes (Servier) 1991; 30:7-9.

75. Menon RK, Grace A, **Fonseca V,** Burgoyne W, James I, Dandona P. Muscle blood flow in diabetes mellitus: evidence of abnormality following exercise. Diabetes Care 1992, 15:693-5.

76. Gill J, **Fonseca V**, Jeremy J, Dandona P. Lisinopril inhibits beta-adrenoceptor-linked calcium uptake by platelets from hypertensive diabetic patients. Br J Clin Pharm 1992, 33:161-5.

77. **Fonseca V**. and Bouloux P.M.G. Pheochomocytoma and paragangliomas: clinical aspects. Baillieres Clin in Endocrinol and Metab. 1993, 7:509-44.

78. Munshi M, Martin R, **Fonseca V.** Hyperosmolar Non-ketotic Diabetic syndrome following treatment of HIV infection with Didanosine. Diabetes Care, 1994; 17: 316-317.

79. **Fonseca. V**, Wall J. Diet, Diabetes and the elderly. Clin Geriatr Med 1995; 4: 613-624

80. **Fonseca V**, Munshi M, Merin L, Bradford JD. Diabetic retinopathy - a review for the primary care physician. Southern Med J 1996, 89: 839 -850.

81. Munshi M, Stone A, Fink L, **Fonseca V.** Hyperhomocysteinemia following a methionine load in non-insulin dependent diabetes and macrovascular disease. Metabolism, 1996; 45:133 -135.

82. Guba S, **Fonseca V**, Fink L. Hyperhomocysteinemia - the emerging and important risk factor for cardiovascular disease. Am J Clin Pathol; 1996; 106: 709 -722.

83. Hinson J, Riordan K, Hemphill D, Randolph C, **Fonseca V**. Hypertension education, a neglected part of the diabetes education curriculum? Diabetes Educator, 1997, 23: 166 – 170.

84. Baliga BS, **Fonseca V**. Recent advances in the treatment of non-insulin dependent diabetes mellitus. American Family Physician. 1997, 55: 817 -824.

85. **Fonseca V**. Applicability of DCCT to NIDDM and standards of care in diabetes. Federal Practitioner 1997, suppl. 9 -13.

86. **Fonseca V**. The importance of patient education and the pharmacological treatment of diabetes. Federal Practitioner 1997, suppl. 18-22.

87. **Fonseca V**, Hinson J, Pappas A, Waner M, Flock S. A portable Er: YAG laser to obtain blood samples for laboratory testing without a needle. Arch Pathol Lab Med 1997; 121: 685 -688.

88. Gardner SF, Marx MA, White LM, Granberry MC, Skelton DR, **Fonseca VA**. A combination of low-dose niacin and pravastatin improves the lipid profile without compromising glycemic control. Annals of Pharmacotherapy, 1997, 31: 677 -682.

89. **Fonseca VA**, Stone A, Munshi M, Baliga BS, Aljada A, Thusu K, Fink L, Dandona P. Oxidative stress in diabetes mellitus: Does homocysteine have a role? Southern Med J 1997; 90: 903 - 906.

90. Schwartz S, Raskin P, **Fonseca V**, Graveline J. The effect of Troglitazone on glycemic control in insulin treated non-insulin-dependent diabetes Mellitus. N Engl J Med 1998, 338: 861 –866.

91. **Fonseca V**, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquett T, Graveline J, Fink L. The effect of troglitazone on Fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diab Compl 1998, 12: 181–186.

92. **Fonseca V,** Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in diabetic but not type II diabetic subjects. Metabolism, 1998, 47: 686–689.

93. **Fonseca V,** Valiquett TR, Huang SM, Ghazzi MN, Whitcomb R. Troglitazone Monotherapy Therapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study. J Clin. Endo Metab 1998; 83: 3169 –76.

94. **Fonseca V.** Screening and management of diabetic nephropathy and neuropathy. Fed. Practitioner. 1998: 15: 9 –13

95. Backonja M, Beydoun A, Edwards KR, Schwartz SL, **Fonseca V**, Garofalo E, Hes M, LaMoreaux L. Treatment of painful neuropathy: a randomized, double –blind, placebo controlled trial in patients with diabetes mellitus. JAMA, 1998; 280: 1831 –36.

96. Washam J, Wall J, Riordan K, Hemphill D, Randolph C, **Fonseca V**. Blood Pressure: Are you in control? Diabetes Forecast 1998; 51: (5) 40 –46.

97. Barhoum M, Hutchins L, **Fonseca V**. Intractable Hypercalcemia due to a metastatic carcinoid secreting PTHrP and IL-6: response to Octreotide. Am J Med Sci 1999; 318: 203–205.

98. Granberry M, Baliga S, **Fonseca V**. Pathophysiology of painful diabetic neuropathy: The role of Gabapentin in treatment. Practical Diabetology 1999; 18: 6 –11.

99. Granberry M, **Fonseca V**. The insulin resistance syndrome: treatment options. S Med J. 1999; 92: 2 –14.

100. Guba S, **Fonseca V**, Fink L. Hyperhomocysteinemia and thrombosis. Seminars in hemostasis. 1999; 25: 291 –299.

101. **Fonseca V,** Ethics of placebo –controlled trials in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 1999 82: 823 – 824

102. Anand MM, **Fonseca V.** Endothelial Dysfunction and type 2 diabetes. Practical Diabetology 1999; 18: 23 –27.

103. Granberry MC, Schneider EF, **Fonseca VA**. Treating the insulin resistance syndrome: the role of troglitazone. Pharmacotherapy, 1998; 18: 973-987.

104. Das S, Reynolds T, Patnaik A, Rais N, Fink LM**, Fonseca V**. Plasma homocysteine concentrations in type 2 diabetics in India: relationship to body weight. J Diab Compl 1999; 13: 200-203

105. **Fonseca V.** Improving glycemic control and overcoming insulin resistance: the key to preventing cardiovascular disease in diabetes. http://endocrine.medscape.com/ Medscape/endocrinology/TreatmentUpdate/1999

106. **Fonseca V,** Guba S, Fink L. Hyperhomocysteinemia and the endocrine system. Endocrine Reviews 1999; 20: 738 –759.

107. Gill JK. **Fonseca V**. Dandona P. Mikhailidis DP. Angelini GD. Jeremy JY. Differential alterations of spontaneous and stimulated 45Ca(2+) uptake by platelets from patients with type I and type II diabetes mellitus. Journal of Diabetes & its Complications. 1999, 13:271-6.

108. **Fonseca V,** Foyt H, Shen K, Whitcomb R. Long–term effects of Troglitazone: open–label extension studies in type 2 diabetes patients. Diabetes Care 2000; 23: 354 –359.

109. **Fonseca V,** Rosenstock J, Biswas N, Salzman A. Once daily Rosiglitazone in combination with Metformin effectively reduces hyperglycaemia in patients with type 2 diabetes. JAMA 2000, 283: 1695 -1702.

110. **Fonseca V,** Dicker -Brown A, Ranganathan S, Barnard RJ, Fink L, Kern PA. Effects of a high fat sucrose diet on enzymes of homocysteine metabolism in the rat. Metabolism; 2000; 49: 736 -741.

111. Cranmer M, Louie S, Kennedy RH, Kern PA, **Fonseca V**. Exposure to 2, 3, 7, 8-tetrachlorobenzo–p- dioxin (TCDD) is associated with hyperinsulinemia and insulin resistance. Toxicological Sciences, 2000; 56: 431 –436.

112. Baliga S, Reynolds T, Fink L, Fonseca V. Hyperhomocysteinemia in type 2 diabetes: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocrine Practice, 2000; 6: 435 -441.

113. Brown A, **Fonseca V**, Fink L, Kern PA. The effect of glucose and insulin on enzymes in homocysteine metabolism: studies in HEP G2 cells. Atherosclerosis, 2001 158: 297 –301.

114. Parulkar A, Pendergrass M, Lee TR, Granda–Ayala R, **Fonseca V**. Non hypoglycemic effects of Thiazolidinediones. Ann Int Med, 2001; 134: 61 –71.

115. **Fonseca V.** Pioglitazone – a viewpoint. Drugs; 2000; 60; 344 -5.

116. **Fonseca V**. Risk factors for coronary heart disease in diabetes mellitus. (Invited Editorial) Ann Int Med, 2000; 133: 154 –156.

117. Kern PA, Dicker-Brown A, Said ST, Kennedy R, **Fonseca VA**. The stimulation of tumor necrosis factor and inhibition of glucose transport and lipoprotein lipase in adipose cells by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Metabolism. 2002; 51:65-8.

118. DeSouza C, Khan M**, Fonseca V**. Coronary Heart Disease in Type 2 Diabetes: The End result of the Insulin Resistance Syndrome. J Clinical Outcomes Management. 2000, 7:50 -59.

119. Keebler ME, De Souza C, **Fonseca V.** Diagnosis and treatment of hyperhomocysteinemia. Current Atherosclerosis Reports. 2001, 1; 54 -63.

120. Koshy P, Self A, Kadowitz PJ, **Fonseca VA**, McNamara DB. Effects of low dose Candesartan on the rate of re-endothelialisation following vascular wound healing. J of the Renin-Angiotensin-Aldosterone System. 2001; 2: Suppl 1, S81-83.

121. De Souza C, **Fonseca V.** Insulin sensitizer combination therapy for type 2 diabetes. Cardiology Review, 2001; 18: 11-15.

122. Poirier LA, Brown AT, Fink, LM. Wise CK, Randolph CJ, Delongchamp RR, **Fonseca V**. Blood s-adenosylmethionine concentration and lymphocyte methylene-tetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism, 2001; 50: 1014 –18.

123. De Souza C, Keebler M, McNamara DB, **Fonseca V**. Drugs and Homocysteine Metabolism. Drugs; 2002; 62; 605-616.

124. Kern PA, Fishman, RB, Song W, Brown A, **Fonseca V**. The effect of 2, 3, 7, 8-tetrachlorobenzo –p- dioxin (TCDD) on oxidative enzymes in adipocytes and liver. Toxicology, 2002, 171: 117- 125

125. **V Fonseca,** K Poole, M Keebler, L Poirier, D B. McNamara. The effect of troglitazone on plasma homocysteine concentrations in Zucker obese and lean rats. Metabolism, 2002, 51: 783 -86

126. DeSouza C. Parulkar A, Lumpkin, D, Akers D, **Vivian Fonseca.** Acute and Chronic effects of Sildenafil on flow mediated dilatation in type 2 diabetes. Diabetes Care, 2002, 25: 1336 –1339.

127. Suwattee P, DeSouza C, Asnani, Gilling L, **Fonseca VA**. Cardiovascular Effects of Thiazolidinediones. The Endocrinologist; 2002; 12: 126 -134.

128. Gilling L, Suwattee P, DeSouza C, Asnani, **Fonseca VA**. Cardiovascular Effects of Thiazolidinediones – what is the net effect? Am J Cardiovascular Drugs; 2002; 2: 149 – 156.

129. Asnani S, Desouza C, Homan J, Murthy SN, McNamara DB, **Fonseca V**. Hormones and homocysteine. Minerva Endocrinol 2002;27:141-55

130. Schiller NK, Timothy AM, Aurora HS, Chen IL, Coy DH, Murphy WA, Akers DL, **Fonseca VA**, Kadowitz Pj, McNamara DB. A selective somatostatin type –2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following arotic balloon injury in the rabbit. Molecular and Cellular Biochemistry. 2002;240:31-7

131. Burke AP, **Fonseca V**, Kolodgie F, Zieske A, Fink L, Virmani R. Increased serum homocysteine and sudden death due to coronary atherosclerosis with fibrous plaques. Arteriosclerosis, Thrombosis and Vascular Biology, 2002; 22: 1936 –1941.

132. Gouda BP, Asnani S, **Fonseca VA**. Effects of Thiazolidinediones on cardiovascular risk factors. Comprehensive Therapy; 2002; 28; 200-206

133. DeSouza C, Salazar H, Murgo J, **Fonseca V**. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 1485 -1489.

134. Theuma P, **Fonseca V**. Inflammation and Emerging Risk Factors in diabetes and atherosclerosis. Current Diabetes Reports, 2003, 3: 248 –254.

135. **V Fonseca**, G Grunberger, S Gupta, S Shen,,J E. Foley. Addition of Nateglinide to Rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003 26: 1685-1690.

136. Obregon D, Murthy SN, McNamara DB, **Fonseca VA**. Novel approaches to the treatment of hyperhomocysteinemia. Expert Opinion on Therap Patents; 2003, 13: 1023 –1025.

137. Kendall DM, Sobel BE, Coulston AM, Peters Harmel AL, McLean BK, Peragallo-Dittko V, Buse JB, **Fonseca VA**, Hill JO, Nesto RW, Sunyer FX; The Partners Against Insulin Resistance Advisory Panel.The insulin resistance syndrome and coronary artery disease. Coron Artery Dis. 2003; 14:335-48.

138. **Fonseca VA**.,Fink LM,Kern Philip A. Insulin Sensitivity and Plasma Homocysteine Concentrations in Non-diabetic Obese and Normal-weight Subjects. Atherosclerosis; 2003; 167: 105-109

139. **Fonseca V**. Management of diabetes and insulin resistance in patients with cardiovascular disease. Am J Cardiol, 2003; 18; 92:50-60.

140. Theuma P, **Fonseca V**. Novel cardiovascular risk factors and microvascular and macrovascular complications of diabetes. *Current Drug Targets*-Hot Topics, 2003; 4: 477-486.

141. Chen J, Muntner P, Hamm L, **Fonseca V**, Batuman V, Whelton PK, He J. Insulin Resistance and Risk of Chronic Kidney Disease in Non-Diabetic US Adults. J Am Soc Nephrol; 2003; 14:469-77

142. Richard BC, Asnani S, DeSouza C, **Fonseca V**. Is weight loss possible in patients treated with Thiazolidinediones? Experience with very low calorie diets. Curr Med Res and Opinion 2003; 19(7):609-13.

143. Kcomt J, Richard B, Lynch JC, **Fonseca V**. Education in the treatment of hypertension associated with diabetes mellitus. In Hypertension and Diabetes, Lippincott and Williams; Ed Mogensen CE; Vol 3, 2003; 61-76.

144. Asnani S, Chan E, Murthy SN, McNamara DB,. Fonseca VA, Effect of pharmacological treatments for diabetes on homocysteine. J Metabolic Syndrome; 2003, 1: 149-158.

145. Chan E, **Fonseca VA**. Management of Hyperhomocysteinemia. J Metabolic Syndrome; 2003, 1: 159-170

146. Gilling, L., Suwattee, P., Desouza, C., Asnani, S. and **Fonseca, V**. Effects of the thiazolidinediones on cardiovascular risk factors. 2002. Am J Cardiovasc. Drugs 2: 149-156.

147. Nesto RW, Bell D, Bonow RO, **Fonseca V**, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: A Consensus Statement From the American Heart Association and American Diabetes Association. Circulation 2003; 108(23): 2941-2948

148. **Fonseca V**. Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Am J Med. 2003 Dec 8;115 Suppl 8A:42S-48S

149. Desouza, C. V., Murthy, S. N., Diez, J., Dunne, B., Matta, A. S., **Fonseca, V. A**. and McNamara, D. B. Differential effects of peroxisome proliferator activator receptor-alpha

and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc. Pharmacol. Ther. 2003; 8: 297-305.

150. Mzayek F, Sherwin R, **Fonseca V**, Valdez R, Srinivasan SR, Cruickshank JK, MD; Berenson GS. Differential Association of Birth Weight with Cardiovascular Risk Variables in Blacks and Whites: The Bogalusa Heart Study. Annals of Epidemiology; 2004; 14:258-64.

151. Chen, J., Muntner, P., Hamm, L. L., Jones, D. W., Batuman, V., **Fonseca, V**., Whelton, P. K. and He, J. The metabolic syndrome and chronic kidney disease in U.S. adults. 2004. Ann. Intern. Med 140: 167-174

152. **Fonseca V**, Desouza C, Asnani S, Jialal I. Non –traditional risk factors for cardiovascular disease in Diabetes. Endocrine Reviews, 2004; 25: 153-175.

153. The NAVIGATOR Trial Steering Committee. Prevention of Diabetes and Cardiovascular Disease in Patients with Impaired Glucose Tolerance: Rationale and Design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Submitted 2004

154. **Fonseca VA**, Kelley DE, Baron MA, Marcellari AH. Hypoglycemic Potential of Nateglinide vs. Glyburide in Patients with Type 2 Diabetes Mellitus. 2004, Metabolism, Metabolism. 2004;53:1331-5

155. Muntner P, He J, Chen J, **Fonseca V**, Whelton PK. Increased Prevalence of Traditional and Non-traditional Cardiovascular Disease Risk Factors Among Persons with Impaired Fasting Glucose and Diabetes: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004; 14:686-95.

156. **Fonseca V**. Single-composition extended-release metformin hydrochloride. Treat Endocrinol. 2004;3:333-4

157. Jawa A, Kcomt J, **Fonseca VA**. Diabetic nephropathy and retinopathy. Med Clin North Am. 2004;88:1001-36

158. Bakris GL, **Fonseca V,** Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004; 292:2227-36.

159. **Fonseca VA**, Diez J, McNamara DB. Decreasing restenosis following angioplasty: the potential of peroxisome proliferator-activated receptor gamma agonists. Diabetes Care. 2004; 27:2764-6.

160. **Fonseca V**, Bell DS, Berger S, Thomson S, Mecca TE.A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci. 2004; 328:274-280.

161. **Fonseca V**, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004; 47:1914-23.

162. Tolman KG, **Fonseca V**, Tan MH, Dalpiaz A.Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med. 2004 Dec 21; 141(12):946-56.

163. Leroith D, **Fonseca V**, Vinik A. Metabolic memory in diabetes-focus on insulin.Diabetes Metab Res Rev. 2004 Dec 24

164. **Fonseca, V**: Effect of intensive treatment on vascular and other complications of diabetes mellitus. *Clin Cornerstone.* 6:40-50, 2004

165. Rappaport,J, **Fonseca,V**: Case-Based Study: From Prediabetes to Complications-Opportunities for Prevention. *PLoS.Med* 2:127-131, 2005

166. Jawa,AA, **Fonseca,VA**: Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. *Cardiol.Clin* 23:119-138, 2005

167. Panunti,B, Kunhiraman,B, **Fonseca,V**: The impact of antidiabetic therapies on cardiovascular disease. *Curr.Atheroscler.Rep.* 7:50-57, 2005

168. Matfin,G, Jawa,A, **Fonseca,VA**: Erectile dysfunction: interrelationship with the metabolic syndrome. *Curr.Diab.Rep.* 5:64-69, 2005

169. Bakris GL, Bell DS, **Fonseca V**, Katholi R, McGill J, Phillips R, Raskin P, Wright JT, Iyengar M, Holeslaw T, Anderson KM, GEMINI investigators. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005; 19:74-9.

170. Kunhiraman B, Jawa A, **Fonseca VA**. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am. 2005; 34:117-35.

171. Murthy SN, Obregon DF, Chattergoon NN, Fonseca NA, Mondal D, Dunne JB, Diez JG, Jeter JR, Kadowitz PJ, Agrawal KC, McNcamara DB, **Fonseca VA**. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism. 2005; 54:645-52.

172. Granberry MC, **Fonseca VA**. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005; 5:201-9.

173. Reynolds K, Muntner P, **Fonseca V**. Metabolic Syndrome: Underrated or underdiagnosed? Diabetes Care. 2005; 28:1831-2.

174. Kostis, J. B., Jackson, G., Rosen, R., Barrett-Connor, E., Billups, K., Burnett, A. L., Carson, C., III, Cheitlin, M., DeBusk, R., **Fonseca, V.,** Ganz, P., Goldstein, I., Guay, A., Hatzichristou, D., Hollander, J. E., Hutter, A., Katz, S., Kloner, R. A., Mittleman, M., Montorsi, F., Montorsi, P., Nehra, A., Sadovsky, R. and Shabsigh, R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). 2005. Am J Cardiol. 96: 313-321.

175. **Fonseca V**, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005; 96(12B):13M-18M.

176. Muntner, P., Wildman, R. P., Reynolds, K., Desalvo, K. B., Chen, J. and **Fonseca, V**. Relationship between HbA1c level and peripheral arterial disease. 2005. Diabetes Care 28: 1981-1987.

177. Deedwania PC, **Fonseca VA**. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med. 2005; 118: 939-947.

178. Bakris GL, **Fonseca V,** Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005; 46:1309-15.

179. **Fonseca VA**. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin Cornerstone 2005; 7(2-3):61-72

180. Cefalu WT, Smith SR, Blonde L, **Fonseca V**. The Hurricane Katrina Aftermath and Its Impact on Diabetes Care: Observations from "ground zero": lessons in disaster preparedness of people with diabetes. Diabetes Care. 2006; 29:158-60.

181. **Fonseca V,** Jawa A, Asnani S**.** THE PROACTIVE STUDY: The Glass is Half Full. J Clin Endocrinol Metab. 2006; 91:25-7.

182. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, **Fonseca V**. Impaired Vascular Reactivity In African-American Patients With Type 2 Diabetes Mellitus And Microalbuminuria or Proteinuria Despite Angiotensin Converting Enzyme Inhibitor Therapy. J Clin Endocrinol Metab. 2006; 91:31-35.

183. **Fonseca VA.** Insulin resistance, diabetes, hypertension, and Renin-Angiotensin system inhibition: reducing risk for cardiovascular disease. J Clin Hypertens (Greenwich) 2006; 8(10):713-720

184. **Fonseca V.** Newly diagnosed diabetes/hyperglycemia in hospitals: what should we do? Endocr Pract 2006; 12 Suppl 3:108-111.

185. Panunti B, **Fonseca V**. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol 2006; 45(1):29-35

186. Schwartz S, **Fonseca V,** Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29(4):759-764.

187. **Fonseca VA**, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications 2006; 20(1):14-20.

188. Vasudevan AR, Burns A**, Fonseca VA**. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 2006; 5:273-286.

189. **Fonseca VA**. Insulin resistance, diabetes, hypertension, and Renin-Angiotensin system inhibition: reducing risk for cardiovascular disease. J Clin Hypertens (Greenwich) 2006; 8(10):713-720.

190. Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpin D, **Fonseca V**. Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin. Metabol Synd Rel Disorders Sep 2006, 4: 179-184

191. **Fonseca VA**, Kahn SE. Of HOPEs and DREAMs: the quest to prevent type 2 diabetes. J Clin Endocrinol Metab 2006; 91:4762-4763. (Invited Editorial)

192. Jawa A, **Fonseca V.** Cardiovascular effects of insulin sensitizers in diabetes. Curr Opin Investig Drugs 2006; 7(9):806-814.

193. Buse JB, Ginsberg HN, Bakris GL, Clark NG, **Fonseca V** et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115(1):114-126.

194. **Fonseca V**. Diabetes care: building on strength. Diabetes Care 2007; 30(1):1-2.

195. Shah SV, Baliga R, Rajapurkar M, **Fonseca VA**. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18(1):16-28.

196. **Fonseca V**. Management of diabetes in the hospital. Rev Cardiovasc Med. 2006;7 Suppl 2:S1

197. Tolman KG, **Fonseca V**, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007; 30:734-43.

198. Thethi T, Bratcher C, F**onseca V**. Metabolic syndrome and heart failure. Heart Fail Clin. 2006; 1-11.

199. McGill JB, Bakris GL, **Fonseca V,** Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. Beta-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007; 9:408-17.

200. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, **Fonseca V** et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am.J.Cardiol. 2007; 18; 99 (12A):80i-89i.

201. **Fonseca V**, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet.Med. 2007; 24: 759-763.

202. **Fonseca V**, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.

203. Messerli FH, Bell DS, **Fonseca V**, Katholi RE, McGill JB, Phillips RA, et al. Body weight changes with beta-blocker use: results from GEMINI. Am.J.Med. 2007; 120: 610-615.

204. Swaminathan S, **Fonseca VA**, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007; 30:1926-1933.

205. Tolman KG, **Fonseca V**, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30:734-743.

206. Zhang R, Florman S, Devidoss S, Zarifian A, Yau CL, Paramesh A, **Fonseca V**,et al. A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am.J.Transplant. 2007; 7:1815-1821.

207. Uppu RM, Nossaman BD, Greco AJ, Fokin A, Murthy SN, **Fonseca VA**, et al. Cardiovascular effects of peroxynitrite. Clin.Exp.Pharmacol.Physiol. 2007; 34:933-937.

208. Disaster Response Task Force (**Fonseca V**, Chair). American Diabetes Association Statement on Emergency and Disaster Preparedness: a report of the Disaster Response Task Force. Diabetes Care 2007; 30: 2395-2398.

209. Bell DS, McGill JB, Fonseca VA. The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin. Endocr Pract. 2007; 13(7):808-9.

210. **Fonseca VA**. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med. 2007; 120(9 Suppl 2):S18-25.

211. Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: Results from GEMINI. Diabet Med. 2007; 24(7):759-63.

212. Wright JT,Jr, Bakris GL, Bell DS, **Fonseca V**, Katholi RE, McGill JB, et al. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: Results from the GEMINI trial. J Clin Hypertens (Greenwich). 2007; 9(11):842-9.

213. Zhang R, Florman S, Devidoss S, Zarifian A, Killackey M, Paramesh A, **Fonseca V** et al. The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin Transplant. 2007; 21(5):583-9.

214. Bakris G, **Fonseca V**, Foody J. Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008; 3:119-25.

215. Engel-Nitz NM, Martin S, Sun P, Buesching D, **Fonseca V**. Cardiovascular events and insulin therapy: A retrospective cohort analysis. Diabetes Res Clin Pract. 2008; 81:97-104.

216. **Fonseca V**, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus *. Horm Metab Res. 2008; 40:427-30.

217. **Fonseca VA**, Kulkarni KD. Management of type 2 diabetes: Oral agents, insulin, and injectables. J Am Diet Assoc. 2008; 108:S29-33.

218. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, **Fonseca V**. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in african-american subjects with diabetes and hypertension. J Diabetes Complications. 2008 Apr 15.

219. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC,Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59.

220. Goldberg RB, **Fonseca VA**, Truitt KE, Jones MR: Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. *Arch Intern Med.* 168:1531-1540, 2008.

221. Kahn R, **Fonseca V**: Translating the A1C assay. *Diabetes Care.* 31:1704-1707, 2008.

222. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, **Fonseca V**: Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: A meta-analysis of randomized controlled trials. *Diabet Med.* 25:924-932, 2008

223. **Fonseca VA**, Rosenstock J, Wang AC, Truitt KE, Jones MR: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. *Diabetes Care.* 31:1479-1484, 2008

224. Krane NK, Anderson D, Lazarus CJ, Termini M, Bowdish B, Chauvin S, **Fonseca V**: Physician practice behavior and practice guidelines: Using unannounced standardized patients to gather data. *J Gen Intern Med.* , 2008

225. McDuffie R, Summerson J, Reilly P, Blackwell C, Goff D, Kimel AR, Crago L, **Fonseca V**: The action to control cardiovascular risk in diabetes (ACCORD) trial and hurricane katrina: Lessons for managing clinical trials during and after a natural disaster. *Contemp Clin Trials.* 29:756-761, 2008

226. Wani JH, John-Kalarickal J, **Fonseca VA**: Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: A systematic review. *Cardiol Clin.* 26:639-648, 2008

227. Rao AD, Kuhadiya N, Reynolds K, **Fonseca VA**: Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. *Diabetes Care.* 31:1672-1678, 2008

228. Phillips RA, **Fonseca V**, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT,Jr, Iyengar M, Anderson KM, Lukas MA, Bakris GL, GEMINI Investigators: Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the glycemic effects in diabetes mellitus: Carvedilol-metoprolol comparison in hypertensives (GEMINI) study. *J Cardiometab Syndr.* 3:211-217, 2008

229. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, **Fonseca V**, Garvey WT, Gavin JR,3rd, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW: Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American college of endocrinology and the American association of clinical endocrinologists. *Endocr Pract.* 14:933-946, 2008

230. Bakris G, **Fonseca V**, Foody J: Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. *J Cardiometab Syndr.* 3:119-125, 2008

231. Ferrannini E, **Fonseca V**, Zinman B, Matthews D, Ahren B, Byiers S, Shao Q, Dejager S: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab.* 11:157-166, 2009

232. Krane NK, Anderson D, Lazarus CJ, Termini M, Bowdish B, Chauvin S, **Fonseca V**: Physician practice behavior and practice guidelines: Using unannounced standardized patients to gather data. *J Gen Intern Med.* 24:53-56, 2009

233. McNamara DB, Murthy SN, Fonseca AN, Desouza CV, Kadowitz PJ, **Fonseca VA**: Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. *Can J Physiol Pharmacol.* 87:37-50, 2009

234. Bakris GL, **Fonseca VA**, Sharma K, Wright EM: Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. *Kidney Int.* 75:1272-1277, 2009

235. DeSouza C, **Fonseca V**: Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. *Nat Rev Drug Discov.* 8:361-367, 2009

236. **Fonseca VA**: Demystifying incretin therapy for type 2 diabetes. *Am J Med.* 122:S1-2, 2009

237. Goldfine AB, **Fonseca VA**: The use of colesevelam HCl in patients with type 2 diabetes mellitus: Combining glucose- and lipid-lowering effects. *Postgrad Med.* 121:13-18, 2009

238. Rosenstock J, **Fonseca V**, McGill JB, Riddle M, Halle JP, Hramiak I, Johnston P, Davis M: Similar progression of diabetic retinopathy with insulin glargine and neutral protamine hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study. *Diabetologia.* , 2009; 52(9):1978-88.

239. Surampudi PN, John-Kalarickal J, **Fonseca VA**: Emerging concepts in the pathophysiology of type 2 diabetes mellitus. *Mt Sinai J Med.* 76:216-226, 2009

240. Rhoads GG, Kosiborod M, Nesto RW, **Fonseca VA**, Lu SE, Zhang Q, Foody JM: Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine hagedorn insulin versus insulin glargine. *Am J Cardiol.* 104:910-916, 2009

241. Murthy SN, Sukhanov S, McGee J, Greco JA, Chandra S, Delafontaine P, Kadowitz PJ, McNamara DB, **Fonseca VA**: Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in zucker fatty rats possibly by reduction in oxidative stress. *Mol Cell Biochem.* , 2009;330:1-8

242. Murthy SN, Akers DL,Jr, Chen IL, Osgood TA,Jr, Santiago R, **Fonseca VA,** Kadowitz PJ, McNamara DB: U74389F, a 21-aminosteroid antioxidant, improves neoendothelial morphology, but not neointimal thickening after balloon catheter injury. *Can J Physiol Pharmacol.* 87:1102-1109, 2009.

243. Kelly TN, Bazzano LA, **Fonseca VA**, Thethi TK, Reynolds K, He J: Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med.* 151:394-403, 2009.

244. **Fonseca VA**, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, Shi L, McDuffie RH, Thethi T, John-Kalarickal J: Impact of a natural disaster on diabetes: Exacerbation of disparities and long-term consequences. *Diabetes Care.* 32:1632-1638, 2009.

245. **Fonseca VA**: Defining and characterizing the progression of type 2 diabetes. *Diabetes Care.* 32 Suppl 2:S151-6, 2009.

246. **Fonseca V**, Inzucchi SE, Ferrannini E: Redefining the diagnosis of diabetes using glycated hemoglobin. *Diabetes Care.* 32:1344-1345, 2009.

247. **Fonseca V**: Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes. *Evid Based Med.* 14:139, 2009.

248. Carson AP, Reynolds K, **Fonseca VA,** Muntner P: Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. *Diabetes Care.* , 2009, 2010;33: 95-7.

249. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, **Fonseca V,** Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training Circulation. 2009; 120: 100-26.

250. Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, **Fonseca V,** Winstead D. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. 2009, 18;9: 80.

251. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, **Fonseca VA**, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B: Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The action to control cardiovascular risk in diabetes (ACCORD) trial. *Diabetes Care.* 33:721-727, 2010

252. Carson AP, Reynolds K, **Fonseca VA**, Muntner P: Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. *Diabetes Care.* 33:95-97, 2010

253. **Fonseca VA**: Effects of beta-blockers on glucose and lipid metabolism. *Curr Med Res Opin.* 26:615-629, 2010

254. **Fonseca VA,** Handelsman Y, Staels B: Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence. *Diabetes Obes Metab.* 12:384-392, 2010

255. Goldfine AB, **Fonseca V,** Jablonski KA, Pyle L, Staten MA, Shoelson SE, TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team: The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. *Ann Intern Med.* 152:346-357, 2010

256. Goldfine AB, **Fonseca VA**, Jones MR, Wang AC, Ford DM, Truitt KE: Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. *Horm Metab Res.* 42:23-30, 2010

257. Murthy SN, Hilaire RC, Casey DB, Badejo AM, McGee J, McNamara DB, Kadowitz PJ, **Fonseca VA**: The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. *Diab Vasc Dis Res.* 7:138-144, 2010

258. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, **Fonseca V**, et al. *N Engl J Med.* 362:1463-1476, 2010

259. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, **Fonseca V**, et al . *N Engl J Med.* 362:1477-1490, 2010

260. Patel AK, **Fonseca V**: Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. *Curr Diab Rep.* 10:101-107, 2010

261. Staels B, Handelsman Y, **Fonseca V**: Bile acid sequestrants for lipid and glucose control. *Curr Diab Rep.* 10:70-77, 2010

262. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC,Jr, Grimm RH,Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F: Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 362:1575-1585, 2010

263. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR,3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC,Jr, Cushman WC, Simons-Morton DG, Byington RP: Effects of

combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 362:1563-1574, 2010

264. Ahren B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S, **Fonseca VA:** Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care.* 33:730-732, 2010

265. Desouza C, Raghavan VA, **Fonseca VA**: The enigma of glucose and cardiovascular disease. *Heart.* 96:649-651, 2010

266. **Fonseca V**, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A: Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials. *Curr Med Res Opin.* , 2010. 26:1621-8.

267. Fonarow GC, Deedwania P, **Fonseca V**, Nesto RW, Watson K, Tarka E, Lukas MA, Madan A, Shabbout M: Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: Results of the extended-release carvedilol lipid trial. *J Am Soc Hypertens.* 3:210-220, 2009

268. Rosenstock J, **Fonseca VA**, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR: Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. *Endocr Pract.* 16:629-640, 2010

269. Ali S, **Fonseca VA**: Diabetes: Low HbA1c levels and mortality in type 2 diabetes mellitus. *Nat Rev Endocrinol.* 6:359-360, 2010

270. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, **Fonseca VA**, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B: Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The action to control cardiovascular risk in diabetes (ACCORD) trial. *Diabetes Care.* 33:721-727, 2010

271. Desouza CV, Bolli GB, **Fonseca V:** Hypoglycemia, diabetes, and cardiovascular events. *Diabetes Care.* 33:1389-1394, 2010

272. **Fonseca V**, Desouza C, Khan AN: Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. *Evid Based Med.* 15:115-116, 2010

273. **Fonseca VA**, Handelsman Y, Staels B: Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence. *Diabetes Obes Metab.* 12:384-392, 2010

274. **Fonseca VA,** Zinman B, Nauck MA, Goldfine AB, Plutzky J: Confronting the type 2 diabetes epidemic: The emerging role of incretin-based therapies. *Am J Med.* 123:S2-S10, 2010

275. Ganda OP, **Fonseca VA:** Salt sensitivity, insulin resistance, and public health in India. *Endocr Pract.* :1-10, 2010

276. Goldfine AB, **Fonseca V**: Management of diabetes mellitus in patients with cardiovascular disease in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Circulation.* 121:2447-2449, 2010

277. Handelsman Y, Goldberg RB, Garvey WT, **Fonseca VA,** Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL: Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized, prospective study. *Endocr Pract.* 16:617-628, 2010

278. Matthews DR, Dejager S, Ahren B, **Fonseca V**, Ferrannini E, Couturier A, Foley JE, Zinman B: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study. *Diabetes Obes Metab.* 12:780-789, 2010

279. Thethi TK, Rao A, Kawji H, Mallik T, Yau CL, Christians U, **Fonseca V**: Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. *J Diabetes Complications.* , 2010; 24:73-8

280. Wildman RP, McGinn AP, Lin J, Wang D, Muntner P, Cohen HW, Reynolds K, **Fonseca V,** Sowers MR: Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities. *Obesity (Silver Spring).* , 2011;19(4):853-60

281. Shi L, Zhao Y, Szymanski K, Yau L, **Fonseca V**: Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. *J Diabetes Complications.* , 2011; 25(3):143-50.

282. Murthy SN, Desouza CV, Bost NW, St Hilaire RC, Casey DB, Badejo AM, Dhaliwal JS, McGee J, McNamara DB, Kadowitz PJ, **Fonseca VA**: Effects of salsalate therapy on recovery from vascular injury in female zucker fatty rats. *Diabetes.* , 59:3240-3246, 2010

283. Shi L, Liu J, **Fonseca V**, Walker P, Kalsekar A, Pawaskar M: Correlation between adherence rates measured by MEMS and self-reported questionnaires: A meta-analysis. *Health Qual Life Outcomes.* 8:99, 2010

284. Shi L, Liu J, Koleva Y, **Fonseca V**, Kalsekar A, Pawaskar M: Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. *Pharmacoeconomics.* 28:1097-1107, 2010

285. Wildman RP, McGinn AP, Kim M, Muntner P, Wang D, Cohen HW, Ogorodnikova AD, Reynolds K, **Fonseca V**: Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk. *Diabetes Care.* 34:746-748, 2011

286. Toprani A, **Fonseca V**: Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. *Diabetes Obes Metab.* 13:276-280, 2011

287. Thethi TK, Parsha K, Rajapurkar M, Mukhopadhyay B, Shah S, Yau CL, Japa S, **Fonseca V**: Urinary catalytic iron in obesity. *Clin Chem.* 57:272-278, 2011

288. Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC,Jr, Probstfield J, Yau CL, Shah S, Christians U, Buse J, **Fonseca V**: Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD trial. *Clin Chem.* 57:341-344, 2011

289. Sacks DB, **Fonseca V**, Goldfine AB: Diabetes: Advances and controversies. *Clin Chem.* 57:147-149, 2011

290. Goldfine AB, **Fonseca V**, Shoelson SE: Therapeutic approaches to target inflammation in type 2 diabetes. *Clin Chem.* 57:162-167, 2011

291. **Fonseca VA**: Exploring the spectrum of incretin therapies: The potential for optimizing patient outcomes. *Am J Med.* 124:S1-2, 2011

292. **Fonseca VA**: Incretin-based therapies in complex patients: Practical implications and opportunities for maximizing clinical outcomes. *Am J Med.* 124:S54-61, 2011

293. **Fonseca V**, Sharma PP, Shah M, Deedwania P: Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. *Curr Med Res Opin.* 27:799-807, 2011

294. Avitabile N, Banka A, **Fonseca VA**: Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. *Expert Opin Drug Saf.* 10:305-310, 2011

295. Arad Y, **Fonseca V**, Peters A, Vinik A: Beyond the monofilament for the insensate diabetic foot: A systematic review of randomized trials to prevent the occurrence of plantar foot ulcers in patients with diabetes. *Diabetes Care.* 34:1041-1046, 2011

296. **Fonseca V**, Gill J, Zhou R, Leahy J: An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia. *Diabetes Obes Metab.* 13:814-822, 2011

297. **Fonseca VA**: Incretin-based therapies in complex patients: Practical implications and opportunities for maximizing clinical outcomes *Am J Med.* 124:S54-61, 2011

298. **Fonseca VA**: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. *Am J Cardiol.* 108:52B-8B, 2011

299. Krause MW, **Fonseca VA**, Shah SV: Combination inhibition of the renin-angiotensin system: Is more better? *Kidney Int.* 80:245-255, 2011

300. Shah SV, **Fonseca VA**: Iron and diabetes revisited. *Diabetes Care.* 34:1676-1677, 2011

301. Avitabile N, Banka A, **Fonseca VA**: Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. *Expert Opin Drug Saf.* 10:305-310, 2011

302. Katsiki N, Papanas N, Mikhailidis DP, **Fonseca VA**: Glycated hemoglobin ac (HbAc) and diabetes: A new era? *Curr Med Res Opin.* 27 Suppl 3:7-11, 2011

303. Zhao Y, Liu J, Zhao Y, Thethi T, **Fonseca V**, Shi L: Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: A retrospective study. *Pain Pract.* , 2011

304. Liu S, Zhao Y, Hempe JM, **Fonseca V**, Shi L: Economic burden of hypoglycemia in patients with type 2 diabetes. *Expert Rev Pharmacoecon Outcomes Res.* 12:47-51, 2012

305. **Fonseca V**, Zhu T, Karyekar C, Hirshberg B: Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. *Diabetes Obes Metab.* 14:365-371, 2012

306. Handelsman Y, **Fonseca V**, Rosenstock J: Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? *Expert Rev Clin Pharmacol.* 5:43-54, 2012

307. Raz I, **Fonseca V**, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R: Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks

of treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). *Diabetes Care.* 35:485-487, 2012

308. **Fonseca VA**, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE, on behalf of the EFC6018 GetGoal-Mono Study Investigators: Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-mono). *Diabetes Care.* 35:1225-1231, 2012

309. Zhao Y, Campbell CR, **Fonseca V**, Shi L: Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. *Diabetes Care.* , 2012

310. Ali S, **Fonseca V**: Saxagliptin overview: Special focus on safety and adverse effects. *Expert Opin Drug Saf.* , 2012

311. Ali S, **Fonseca V**: Overview of metformin: Special focus on metformin extended release. *Expert Opin Pharmacother.* 13:1797-1805, 2012

312. Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, **Fonseca V**: The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. *J Diabetes Complications.* 26:399-406, 2012

313. Zhao Y, Liu J, Zhao Y, Thethi T, **Fonseca V**, Shi L: Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: A retrospective study. *Pain Pract.* 12:366-373, 2012

314. Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, **Fonseca V**: Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: A retrospective database analysis in the united states. *Endocr Pract.* 18:700-711, 2012

315. Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, **Fonseca V**, EASIE investigators: Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): A multicentre, randomised open-label trial. *Lancet.* 379:2262-2269, 2012

316. Avitabile NA, Banka A, **Fonseca VA**: Glucose control and cardiovascular outcomes in individuals with diabetes mellitus: Lessons learned from the megatrials. *Heart Fail Clin.* 8:513-522, 2012

317. Chaudhuri A, Dandona P, **Fonseca V**: Cardiovascular benefits of exogenous insulin. *J Clin Endocrinol Metab.* 97:3079-3091, 2012

318. **Fonseca VA**, Kirkman MS, Darsow T, Ratner RE: The American Diabetes Association diabetes research perspective. *Diabetes.* 61:1338-1345, 2012

319. Liu S, Zhao Y, Hempe JM, Fonseca V, Shi L: Economic burden of hypoglycemia in patients with type 2 diabetes. *Expert Rev Pharmacoecon Outcomes Res.* 12:47-51, 2012

320. Murthy SN, Pankey EA, Banka AA, Badejo AM,Jr, Wekerle R, Vilija V, Izadpanah R, Kadowitz PJ, **Fonseca VA**: Effects of insulin detemir on balloon catheter injured carotid artery in zucker fatty rats. *J Diabetes Complications.* 26:470-475, 2012

321. **Fonseca V**, Staels B, Morgan JD,2nd, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H: Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. *J Diabetes Complications.* , 2012

322. Wilding JP, Ferrannini E, **Fonseca VA**, Wilpshaar W, Dhanjal P, Houzer A: Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. *Diabetes Obes Metab.* 15:403-409, 2013

323. Thethi T, **Fonseca V**: Comparing diabetes drugs--helping clinical decisions? *Lancet.* 381:93-94, 2013

324. Katsiki N, Papanas N, **Fonseca VA**, Maltezos E, Mikhailidis DP: Uric acid and diabetes: Is there a link? *Curr Pharm Des.* 19:4930-4937, 2013

325. Goldfine AB, **Fonseca V**, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE, Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team*: Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. *Ann Intern Med.* 159:1-12, 2013

326. **Fonseca VA**, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, Denham DS, Bottiglieri T, Sheehan P, Rosenstock J: Metanx in type 2 diabetes with peripheral neuropathy: A randomized trial. *Am J Med.* 126:141-149, 2013

327. **Fonseca VA**, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, Klasen S: Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. *J Diabetes Complications.* 27:268-273, 2013

328. **Fonseca V**: Diabetes mellitus in the next decade: Novel pipeline medications to treat hyperglycemia. *Clin Ther.* 35:714-723, 2013

329. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, **Fonseca VA**: Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes mellitus. *Diabetes Care.* , 2013

330. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35.

331. Seaquist ER, Miller ME, **Fonseca V**, Ismail-Beigi F, Launer LJ, Punthakee Z, Sood A: Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. *J Diabetes Complications.* , 2013 2013 ;27(5):485-91

332. **Fonseca V**, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC, the ACCORD Study Group: Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. *Diabetes Care.* , 2013 ;36(8):2162-8.

333. Aroda VR, **Fonseca VA**: U.S. preventive services task force criteria for diabetes screening: Time to revisit the evidence? *Am J Prev Med.* 45:246-247, 2013

334. Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, Jacobs S, Rizzo M, Peng L, Reyes D, Pinzon I, Fereira ME, Hunt V, Gore A, Toyoshima MT, **Fonseca VA**: Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal plus trial. *Diabetes Care.* 36:2169-2174, 2013

335. Zhao W, Shi L, **Fonseca VA**, He J, Shao D, Zhao J, Chen Q, Yin A: Screening patients with type 2 diabetes for active tuberculosis in communities of china. *Diabetes Care.* 36:e159-60, 2013

336. Henry RR, Staels B, **Fonseca VA**, Chou MZ, Teng R, Golm GT, Langdon RB, Kaufman KD, Steinberg H, Goldstein BJ: Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study. *Diabetes Obes Metab.* 16:223-230, 2014

337. Goldfine AB, Buck JS, Desouza C, **Fonseca V**, Chen YD, Shoelson SE, Jablonski KA, Creager MA, for the TINSAL-FMD (Targeting Inflammation using Salsalate in Type 2 Diabetes - Flow-Mediated Dilation) Ancillary Study Team*: Targeting inflammation

using salsalate in patients with type 2 diabetes (TINSAL): Effects on flow-mediated dilation. *Diabetes Care.* , 2013 ;36(12):4132-9

338. Smiley D, Umpierrez GE, Hermayer K, Newton C, Jacobs S, Olson DE, Khan A, Rizzo M, Peng L, Reyes D, Cardona S, **Fonseca V**: Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes. *J Diabetes Complications.* 2013; 27(6):637-41.

339. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492-503

340. **Fonseca VA**: How to get your paper published paper: An editor's perspective. *J Diabetes Complications.* 28:1-3, 2014

341. Barzilay JI, Jablonski KA, **Fonseca V**, Shoelson SE, Goldfine AB, Strauch C, Monnier VM, TINSAL-T2D Research Consortium: The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. *Diabetes Care.* 37:1083-1091, 2014

342. Rosenstock J, **Fonseca VA**, Gross JL, Ratner RE, Ahren B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA, Harmony 6 Study Group: Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. *Diabetes Care.* 37:2317-2325, 2014

343. Geerlings S, **Fonseca V**, Castro-Diaz D, List J, Parikh S: Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. *Diabetes Res Clin Pract.* 103:373-381, 2014

344. **Fonseca VA**, Haggar MA: Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. *Nat Rev Endocrinol.* 10:276-281, 2014

345. **Fonseca VA**, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J: Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. *J Diabetes Complications.* 28:399-405, 2014

346. **Fonseca VA**: New developments in diabetes management: Medications of the 21st century. *Clin Ther.* 36:477-484, 2014

347. Rosenstock J, **Fonseca V**, Schinzel S, Dain MP, Mullins P, Riddle M: Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. *J Diabetes Complications.* , 2014 Apr 16. : S1056-8727(14)00118-4. doi: 10.1016/j.jdiacomp.2014.04.003. [Epub ahead of print]

348. O'Malley TJ, Fava GE, Zhang Y, **Fonseca VA**, Wu H: Progressive change of intra-islet GLP-1 production during diabetes development. *Diabetes Metab Res Rev.* , 2014

349. Shi Q, Zhao Y, **Fonseca V**, Krousel-Wood M, Shi L. Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009. Diabetes Care. 2014 May; 37(5):1321-8.

350. Ziegler D, **Fonseca V**: From guideline to patient: A review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. *J Diabetes Complications.* 29:146-156, 2015

351. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, Zinman B, Eckel RH: Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the american heart association and american diabetes association. *Circulation.* 130:1110-1130, 2014

352. Mottl AK, Pajewski N, **Fonseca V**, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J: The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD trial. *J Diabetes Complications.* 28:874-879, 2014

353. Umpierrez GE, Reyes D, Smiley D, Hermayer K, Khan A, Olson DE, Pasquel F, Jacobs S, Newton C, Peng L, **Fonseca V**: Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. *Diabetes Care.* 37:2934-2939, 2014

354. Chan JC, Aschner P, Owens DR, Picard S, Vincent M, Dain MP, Pilorget V, Loizeau V, Echtay A, **Fonseca V**: Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. *J Diabetes Complications.* , 2014

355. Wang L, Sawhney M, Zhao Y, Carpio GR, **Fonseca V**, Shi L: Association between colchicine and risk of diabetes among the veterans affairs population with gout. *Clin Ther.* 37:1206-1215, 2015

356. Thethi TK, Katalenich B, Nagireddy P, Chabbra P, Md NK, **Fonseca V**: Role of insulin sensitizers on cardiovascular risk factors in polycystic ovarian syndrome: A meta-analysis. *Endocr Pract.* 21:645-667, 2015

357. Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, **Fonseca VA**: Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. *J Diabetes Complications.* 29:433-437, 2015

358. Stowell SA, Miller SC, **Fonseca V**, Trence D, Berry CA, Blum J: Continuing medical education for promoting shared medical visits in diabetes care. *Clin Diabetes.* 33:28-31, 2015

359. Skyler JS, **Fonseca VA**, Segal KR, Rosenstock J, MSB-DM003 Investigators: Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. *Diabetes Care.* 38:1742-1749, 2015

360. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, **Fonseca VA**: Glycemic and cholesterol control versus single-goal control in US veterans with newly diagnosed type 2 diabetes: A retrospective observational study. *Diabetes Ther.* 6:339-355, 2015

361. Lovre D, **Fonseca V**: Benefits of timely basal insulin control in patients with type 2 diabetes. *J Diabetes Complications.* 29:295-301, 2015

362. Liu S, Hempe JM, McCarter RJ, Li S, **Fonseca VA**: Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. *J Clin Endocrinol Metab.* 100:2364-2371, 2015

363. Kirkman MS, Rowan-Martin MT, Levin R, **Fonseca VA**, Schmittdiel JA, Herman WH, Aubert RE: Determinants of adherence to diabetes medications: Findings from a large pharmacy claims database. *Diabetes Care.* 38:604-609, 2015

364. Kaufman HW, Chen Z, **Fonseca VA**, McPhaul MJ: Surge in newly identified diabetes among medicaid patients in 2014 within medicaid expansion states under the affordable care act. *Diabetes Care.* 38:833-837, 2015

365. Katalenich B, Shi L, Liu S, Shao H, McDuffie R, Carpio G, Thethi T, **Fonseca V**: Evaluation of a remote monitoring system for diabetes control. *Clin Ther.* 37:1216-1225, 2015

366. Kachroo S, Kawabata H, Colilla S, Shi L, Zhao Y, Mukherjee J, Iloeje U, Fonseca V: Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: Analysis of a U.S. commercial database. *J Manag Care Spec Pharm.* 21:243-253, 2015

367. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, **Fonseca V**: The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. *Diabetes Care.* 38:1067-1074, 2015

368. Gu S, Shi J, Tang Z, Sawhney M, Hu H, Shi L, **Fonseca V**, Dong H: Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: A meta-analysis. *PLoS One.* 10:e0126704, 2015

369. Desouza CV, Rosenstock J, Zhou R, Holcomb RG, **Fonseca VA**: Glycated albumin at 4 weeks correlates with A1c levels at 12 weeks and reflects short-term glucose fluctuations. *Endocr Pract.* 21:1195-1203, 2015

370. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 373:232-242, 2015

371. Montanya E, **Fonseca V**, Colagiuri S, Blonde L, Donsmark M, Nauck MA: HbA improvement evaluated by baseline BMI: A meta-analysis of the liraglutide phase 3 clinical trial programme. *Diabetes Obes Metab.* 18:707-710, 2016

372. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, **Fonseca VA**, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE: Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. *Endocr Pract.* 22:84-113, 2016

373. **Fonseca VA**, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W, Consensus Conference Writing Committee: Continuous glucose monitoring: A consensus conference of the american association of clinical endocrinologists and american college of endocrinology. *Endocr Pract.*, 2016

374. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, **Fonseca VA**, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir

MR: American association of clinical endocrinologists and american college of endocrinology position statement on the association of sglt-2 inhibitors and diabetic ketoacidosis. *Endocr Pract.* 22:753-762, 2016

375. Nadkarni GN, Rao V, Ismail-Beigi F, **Fonseca VA**, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG: Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial. *Clin J Am Soc Nephrol.*, 2016

376. Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, **Fonseca V**, LixiLan PoC Study Group: Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: The LixiLan proof-of-concept randomized trial. *Diabetes Care.*, 2016

377. Shi Q, **Fonseca V**, Krousel-Wood M, Zhao Y, Nellans FP, Luo Q, Shi L: Will the affordable care act (ACA) improve Racial/Ethnic disparity of eye examination among US working-age population with diabetes? *Curr Diab Rep.* 16:58-016-0749-z, 2016

378. Zhang Y, Fava GE, Wang H, Mauvais-Jarvis F, Fonseca VA, Wu H: PAX4 gene transfer induces alpha-to-beta cell phenotypic conversion and confers therapeutic benefits for diabetes treatment. *Mol Ther.* 24:251-260, 2016

379. Zhao Y, Kachroo S, Kawabata H, Colilla S, Mukherjee J, **Fonseca V**, Iloeje U, Shi L: Association between hypoglycemia and fall-related fractures and health care utilization in older veterans with type 2 diabetes. *Endocr Pract.* 22:196-204, 2016

380. Zhao Y, Shi Q, Wang Y, **Fonseca V**, Shi L: Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the united states (2005-2009). *J Med Econ.* :1-6, 2016

381. Einhorn D, **Fonseca V**: Revisiting the use of Pioglitazone in the Treatment of Type 2 Diabetes. *Endocr Pract* 2016;22:1343-1346

382. Hernandez M, Ortiz RA, Neninger E, Amador RM, Cala M, Camacho K, Salomon E, Guerra PP, Mendoza I, Sanchez C, Viada C, Gonzalez M, Torres LT, **Fonseca V**, Garcia I, Bello L, Alonso M, Rodriguez MC, Cruz A, Valdes R, Lorenzo G, Cepeda M, Saumel Y, Crombet T: P2.40: CIMAvaxEGF Vaccine for the Treatment of Real-World NSCLC Patients: Track: Immunotherapy. *J Thorac Oncol* 2016;11:S242

383. Lovre D, Htun W, Carrion C, **Fonseca VA**: What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents? *Curr Diab Rep* 2016;16:94

384. Annesley T, Scott M, Bastian H, Fonseca V, Ioannidis JP, Keller MA, Polka J: Biomedical Journals and Preprint Services: Friends or Foes? Clin Chem 2017;63:453-458

385. Bloomgarden ZT, Tunceli K, Liu J, Brodovicz KG, Mavros P, Engel SS, Radican L, Chen Y, Rajpathak S, Qiu Y, Brudi P, **Fonseca V**: Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study. *J Diabetes* 2017;9:677-688

386. **Fonseca V**, Chou E, Chung HW, Gerrits C: Economic burden of hypoglycemia with basal insulin in type 2 diabetes. *Am J Manag Care* 2017;23:114-122

387. **Fonseca V**, Grunberger G: Letter to the Editor. *Endocr Pract* 2017;23:629-632

388. **Fonseca V**: Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". *J Diabetes Complications* 2017;31:1248

389. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, **Fonseca VA**, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE: Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. *Endocr Pract* 2017;23:207-238

390. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, **Fonseca VA**, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M: American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr Pract* 2017;23:1-87

391. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, **Fonseca VA**, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA: American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease - Executive Summary, Complete Appendix to Guidelines available at http://journals.aace.com. *Endocr Pract* 2017;23:479-497

392. Mauvais-Jarvis F, Manson JE, Stevenson JC, **Fonseca VA**: Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. *Endocr Rev* 2017;38:173-188

393. Pollock BD, Chen W, Harville EW, Shu T, **Fonseca V**, Mauvais-Jarvis F, Kelly TN, Bazzano LA: Differential sex effects of systolic blood pressure and low-density lipoprotein cholesterol on type 2 diabetes: Life course data from the Bogalusa Heart Study. *J Diabetes* 2017

394. Pollock BD, Hu T, Chen W, Harville EW, Li S, Webber LS, **Fonseca V**, Bazzano LA: Utility of existing diabetes risk prediction tools for young black and white adults: Evidence from the Bogalusa Heart Study. *J Diabetes Complications* 2017;31:86-93

395. Zhang Y, Wu M, Htun W, Dong EW, Mauvais-Jarvis F, **Fonseca VA**, Wu H: Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. *Sci Rep* 2017;7:7964